Click HERE to see the CDC recommendation for RSV vaccination for adults
You are about to leave a GSK website
You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
Vaccination is available to help protect older adults, including adults with certain chronic conditions who may be at increased risk for severe RSV infection1
Adults
50-74
Adults
≥75
Qualified vaccinators, including pharmacists, nurse practitioners, and other providers (based on state and jurisdictional law) may determine patient eligibility for RSV vaccination based on clinical assessment even in the absence of medical documentation of a named risk condition. Patient attestation is sufficient evidence of the presence of a risk factor; vaccinators should not deny RSV vaccination to a person because of lack of documentation.
Chronic lung or respiratory disease
(eg, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
Chronic liver disease
(eg, cirrhosis)
Chronic cardiovascular disease
(eg, heart failure, CAD, or congenital heart disease [excluding isolated hypertension])
Residence in a nursing home
End-stage renal disease or dependence on hemodialysis
or other renal replacement therapy
Diabetes
complicated by chronic kidney disease, neuropathy, retinopathy, or other end-organ damage, or requiring treatment with insulin or SGLT2 inhibitor
Frailty is a multidimensional geriatric syndrome that reflects a state of increased vulnerability to adverse health outcomes. Although no consensus definition exists, one frequently used tool for determination is the Fried frailty phenotype assessment in which frailty is defined as a clinical syndrome with ≥3 of the following symptoms present: unintentional weight loss (10 lb [4.5 kg] in the past year), self-reported exhaustion, weakness (grip strength), slow walking speed, or low physical activity.3
Healthcare providers caring for adults aged 50 to 74 years residing in these communities may use clinical judgment, knowledge of local RSV epidemiology, and community incidence of RSV-associated hospitalization to recommend vaccination for a broader population in this age group.3
Take steps to inform older adult patients at risk for severe RSV about RSV vaccination.
IDENTIFY
Recognize which of your patients are at increased risk for severe RSV infection
INFORM
Help older adult patients get the information they need about RSV
COMMUNICATE
Start the conversation with older adult patients about getting an RSV vaccination
Explore RSV resources for you and your patients
BMI=body mass index; CAD=coronary artery disease; CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; RSV=respiratory syncytial virus; SGLT2=sodium-glucose cotransporter-2.
Respiratory syncytial virus infection (RSV). RSV in adults. Centers for Disease Control and Prevention. Accessed July 14, 2025. https://www.cdc.gov/rsv/adults
Respiratory syncytial virus infection (RSV). RSV Vaccine Guidance for Adults. Centers for Disease Control and Prevention. Accessed July 10, 2025.https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html
Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR. 2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1